

iZafe Group receives at an early stage pre-orders of 450 Dosell units from its partners

Stockholm, Sweden – iZafe Group AB (publ) (NASDAQ First North: IZAFE B) – a leading life science company focused on the digitalization of medication management, is announcing that it already at an early stage has received in total 450 pre-orders of Dosell units from its partners before 2021. The orders are a result of the new features that have been developed during the past year. Production of the updated version of Dosell will begin during the first quarter of 2021 and deliveries will be carried out successively thereafter.

“We have established a broad partner network in Sweden, Norway, Finland, Italy and most recently in the United States. As previously communicated, we have developed Dosell to become even more user-friendly with the feedback of our partners and their customers. During the first quarter of 2021, production of the new updated version of Dosell will begin and we have thus at an early stage already received 450 pre-orders, which will be delivered in 2021 in pace with the production.” Says Anders Segerström, CEO of iZafe Group.

iZafe Group has in a short time built up increased capacity by establishing a partner network that successfully positioned Dosell as the leading product in drug dispensing. The company has won a number of business deals, signed agreements with new partners and successfully participated in a national procurement of medication dispensing robots in Norway. In addition, a number of pilot projects have been started and implemented with a good response from users and care providers.

“Despite the challenges we, our partners and their customers have faced due to the Covid-19 pandemic, we now see how decision-makers are ready to apply new technology. Our partners have built their organization and created the conditions for a broader sale of Dosell. As our partners note an increasing demand and have learned the product, they want to pre-order the updated version of Dosell at an early stage to be able to deliver quickly. In light of the business we are doing and the pilots that will start next year, we look very positively towards 2021.” Anders Segerström, CEO of iZafe Group, continues.

Contacts

Thomas Ahlerup, Chairman of the board and Investor Contact

E-mail: thomas.ahlerup@izafegroup.com

Phone number: +46-7868-966 300

iZafe Group AB (publ)

Grev Turegatan 11A

114 46 Stockholm

E-mail: ir@izafegroup.com

www.izafegroup.com/investorrelations

About Us

iZafe Group is a Swedish med-tech company that develops and markets medical and digital security solutions to create safer drug handling at home. Our digital medicine dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. Our products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: info@fnca.se. Further information is available at www.izafegroup.com/investorrelations.

Attachments

[iZafe Group receives at an early stage pre-orders of 450 Dosell units from its partners](#)